Cardiovascular health technology assessment: recommendations to improve the quality of evidence
The aim of this article is to review the role of Health Technology Assessment (HTA) organisations in appraising and recommending innovative cardiovascular technologies. We consider how bias impairs the quality of evidence from clinical trials involving cardiovascular healthcare technologies. Finally...
Saved in:
| Main Authors: | Colin Berry, David Corcoran, Kenneth Mangion |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-05-01
|
| Series: | Open Heart |
| Online Access: | https://openheart.bmj.com/content/6/1/e000930.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
What an Interventionalist Needs to Know About MI with Non-obstructive Coronary Arteries
by: Robert Sykes, et al.
Published: (2021-06-01) -
Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials
by: Colin Berry, et al.
Published: (2021-02-01) -
Health technology assessment in the Brazilian National Health System: profile of CONITEC exclusion recommendations, 2012-2023
by: Francielli Salles Pinheiro, et al.
Published: (2024-12-01) -
Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
by: Akshyaya Pradhan, et al.
Published: (2020-01-01) -
There is no evidence that the forest service's goshawk recommendations improve goshawk nest productivity
by: Paul Beier, et al.
Published: (2012-03-01)